An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial

Journal of Crohn's and Colitis

Volumn 3, Issue 1, 2009, Pages 32-37

  Connolly, Mark P ^a   Nielsen, Sandy K ^b   Currie, Craig J ^c   Poole, Chris D ^d   Travis, Simon P L ^e  

^a Global Market Access Solutions   (Switzerland)

^b Ferring Pharmaceuticals AS   (Denmark)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d Pharmatelligence   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cost; Cost effectiveness analysis; Economic evaluation; Mesalazine; Ulcerative colitis

Indexed keywords

CYCLOSPORIN A; INFLIXIMAB; MESALAZINE; PREDNISOLONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH STATUS; HUMAN; LONG TERM CARE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 58849113908     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2008.10.004     Document Type: Article

References (27)

1. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influences. Gastroenterology 126 (2004) 1504-1517
2. Shivananda S., Lennard-Jones J., Logan R., et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 39 (1996) 690-697
3. Bassi A., Dodd S., Williamson P., and Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 53 (2004) 1471-1478
4. Odes S., Vardi H., Friger M., et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 131 (2006) 719-728
5. Boonen A., Dagnelie P.C., Feleus A., et al. The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflamm Bowel Dis Nov 8 (2002) 382-389
6. Reinisch W., Sandborn W.J., Bala M., et al. Response and remission are associated with improved quality of life, employment, and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 13 (2007) 1135-1140
7. Kane S.V. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 23 (2006) 577-585
8. Kane S.V., Cohen R.D., Aikens J.E., and Hanauer S.B. Prevalence of non-adherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 96 (2001) 2929-2933
9. Kane S.V., Huo D., Aikens J., and Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114 (2003) 39-43
10. Dignass A, Vermeire H, Adamek R, et al. Improved remission rates from onceversus twice-daily mesalazine (PENTASA) granules for the maintenance of remission in ulcerative colitis: Results from a multinational randomized controlled trialUEGW Oral presentation; 2007. Abstract OP-G-378.
11. Stange E.F., Travis S.P.L., Vermeire S., et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2 (2008) 1-23
12. Travis S.P.L., Stange E.F., Lémann M., et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2 (2008) 24-62
13. Carter M.J., Lobo A.J., Travis S.P.L., and on behalf of the IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 53 (2004) v1-v16
14. Bebb J.R., and Scott B.B. Systematic review: how effective are the usual treatments for ulcerative colitis?. Aliment Pharmacol Ther 20 (2004) 143-149
15. Marteau P., Probert C.S., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study. Gut 54 (2005) 960-965
16. Curtis L. Unit Costs of Health and Social Care (2007), University of Kent: Personal Social Services Research Unit
17. Collins P. Ulcerative colitis: diagnosis and management. BMJ 333 (2006) 340-343
18. Mortimer D., and Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Mak 28 (2008) 66-89
19. Poole C, Nielsen SK, Currie CJ. Health related utility among adults with remitting ulcerative colitis maintained with oral mesalazine over the long term: findings from the PODIUM study. United European Gastroenterology Week; 2008. Abstract: P0178.
20. Konig H.H., Ulshofer A., Gregor M., et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 14 (2002) 1205-1215
21. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17 (2000) 479-500
22. Claxton K., Sculpher M., McCabe C., et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 14 (2005) 339-347
23. Stinnett A.A., and Mulahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak 18 suppl (1998) S68-S80
24. Rawlins M., and Culyer A.J. National Institute for Clinical Excellence and its value judgments. BMJ 329 (2004) 224-227
25. National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal; May 2004. (Accessed 8 August 2008: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf)
26. NICE. Infliximab for subacute manifestations of ulcerative colitis. Technology Appraisal Guidance 140 April 2008. (Accessed 21 August 2008: http://www.nice.org.uk/nicemedia/pdf/TA140Guidance.pdf)
27. Poritz L.S., Rowe W.A., Swenson B.R., Hollenbeak C.S., and Koltun W.A. Intravenous cyclosporine for the treatment of severe steroid refractory ulcerative colitis: what is the cost?. Dis Colon Rectum 48 9 (2005) 1685-1690